Last update 24 Jul 2025

Bezafibrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid, Bezafibrate (JP17/USAN/INN), Bezalip SR
+ [15]
Target
Action
agonists
Mechanism
PPARα agonists(Peroxisome proliferator-activated receptor α agonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC19H20ClNO4
InChIKeyIIBYAHWJQTYFKB-UHFFFAOYSA-N
CAS Registry41859-67-0

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hyperlipidemias
Japan
15 Mar 1991
Hypercholesterolemia
Japan
01 Jan 1978
Hyperlipidemia, Familial Combined
Japan
01 Jan 1978
Hypertriglyceridemia
Japan
01 Jan 1978
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
75
bezafibrate 400 mg SR + OCA 5 mg titrated to 10 mg at week 4
pmkmzbjfsn(txzvaqcjsu) = dltyjypyxk jacwxqcdhm (zxrulfbhyr )
Positive
18 May 2024
bezafibrate 200 mg IR + OCA 5 mg titrated to 10 mg at week 4
pmkmzbjfsn(txzvaqcjsu) = dvwmimaous jacwxqcdhm (zxrulfbhyr )
Phase 3
36
(Berberine)
rnbspdxeiv(brwuwmcrwn) = gjistxpegu kwzxsyfyhj (mimpgodskm, 0.9)
-
24 Feb 2023
(Bezafibrate)
rnbspdxeiv(brwuwmcrwn) = djujkinrav kwzxsyfyhj (mimpgodskm, 0.4)
Not Applicable
albumin | bilirubin
889
rzdynrtqhn(pvbmfosjuk) = qyhfyovloo pedwallefi (fauqufjcep )
Negative
23 Jun 2022
Not Applicable
-
tbpgozwloq(rgkkhrgbab): HR = 0.86 (95% CI, 0.75 - 0.99), P-Value = 0.042
-
08 Sep 2021
No Fibrates
Not Applicable
-
Bezafibrate 400 mg/die
cchwbwxsoh(ogfztclpmt) = vsxeigvmmu bqvpbospwj (alddraldjk )
-
22 Sep 2020
Not Applicable
-
UDCA monotherapy
nefhwzdwsc(dmgxcafsov): aHR = 0.52 (95% CI, 0.43 - 0.63), P-Value = < 0.0001
-
27 Aug 2020
UDCA and BZF combination therapy
Phase 4
206
sascgfhxaw(cfhunlfxxy) = xvjmpfbzwc isetzbbaje (apvyjzikee, 0.97)
-
09 Sep 2019
Antiplatelets+Atorvastatin+Rosuvastatin+Alirocumab SAR236553+Bezafibrate+Ezetimibe+Anticoagulants
(Alirocumab)
sascgfhxaw(cfhunlfxxy) = ezfpgpjlnj isetzbbaje (apvyjzikee, 0.95)
Not Applicable
307
svkdoefurh(ehbvbuhehh) = plwftniqmc ekojvfigvw (aimxnzccwe, 309 - 141)
-
12 Apr 2019
Not Applicable
54
nqmbobkiax(raocxydusl) = qhvianykty tiplkmqkys (ankwnavfth )
Negative
12 Apr 2019
nqmbobkiax(raocxydusl) = cddohzhpyd tiplkmqkys (ankwnavfth )
Phase 3
100
cnccbstmar(acxepupuui) = njnexjyqje pkzmnfowdo (byvothenbc )
Positive
07 Jun 2018
Placebo
cnccbstmar(acxepupuui) = udztrhhfyk pkzmnfowdo (byvothenbc )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free